|
|
|
23.07.25 - 14:39
|
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (Business Wire)
|
|
|
LOS ANGELES--(BUSINESS WIRE)--$NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, August 6, 2025.
Investor Conference Call:
Niagen Bioscience management will host an investor conference call to discuss the second quarter 2025 financial results and provide a general business update on Wednesday, August 6, at 4:30 p.m. ET. Participants should call in at least 10 minutes before the call. The dial-in information is as follows:
Date: Wednesday, August 6
Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: +1 888 596 4144
Conference ID: 8584242
Webcast link: Niagen Bios...
|
|
|
|
|
|
|
|
|
|
|
|
|
29.04.25 - 14:33
|
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board (Business Wire)
|
|
|
Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research
LOS ANGELES--(BUSINESS WIRE)--$NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB).
Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology, Medicine, and Biological Sciences. He is internationally renowned for pioneering the field of mitochondrial microproteins—newly discovered therapeutic targets for diseases of aging—and has published over 350 scientific papers in top scientific journals focusing on...
|
|
|
28.04.25 - 14:39
|
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 (Business Wire)
|
|
|
LOS ANGELES--(BUSINESS WIRE)--$NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025, which ended March 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 7, 2025.
Investor Conference Call:
Niagen Bioscience management will host an investor conference call to discuss the first quarter 2025 financial results and provide a general business update on Wednesday, May 7, 2025, at 4:30 p.m. ET. Participants should call in at least 10 minutes before the call. The dial-in information is as follows:
Date: Wednesday, May 7, 2025
Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: +1 888 596 4144
Conference ID: 8584242
Webcast link: Nia...
|
|
|
|
|
|
|
04.03.25 - 22:06
|
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results (Business Wire)
|
|
|
Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior year, gross margin of 62.5%, and net income of $7.2 million.
LOS ANGELES--(BUSINESS WIRE)--$CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results.
Fourth Quarter 2024
Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter.
Posted strong gross margin of 62.5%, up 150 basis points from 61.0% in the prior year quarter.
General and administrative expense decreased $4.4 million, which includes a $3.5 million reversal of previously accrued royalties and license maintenance fees and a $1.3 million recovery of credit losses related to the legal settlement with Elysium He...
|
|
|
25.02.25 - 22:12
|
ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025 (Business Wire)
|
|
|
LOS ANGELES--(BUSINESS WIRE)--$CDXC #2024Earnings--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2024 financial results, which ended December 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, March 4, 2025.
Investor Conference Call:
ChromaDex management will host an investor conference call to discuss the fourth quarter and fiscal year 2024 results and provide a general business update on Tuesday, March 4, 2025, at 4:30 p.m. ET. Participants should call in at least 10 minutes before the call. The dial-in information is as follows:
Date: Tuesday, March 4, 2025
Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: 888.596.4144
Conference ID: 8584242
Webcast link: ChromaDex...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
